JP2019521989A5 - - Google Patents

Info

Publication number

JP2019521989A5

JP2019521989A5 JP2018565844A JP2018565844A JP2019521989A5 JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5 JP 2018565844 A JP2018565844 A JP 2018565844A JP 2018565844 A JP2018565844 A JP 2018565844A JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5

Authority

JP

Japan

Prior art keywords

item

composition

use according

administration

suspension

Prior art date

2017-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 58
• 239000000203 mixture Substances 0.000 claims description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 239000000725 suspension Substances 0.000 claims description 15
• 238000002347 injection Methods 0.000 claims description 13
• 239000007924 injection Substances 0.000 claims description 13
• 229960000397 bevacizumab Drugs 0.000 claims description 10
• 229960003876 ranibizumab Drugs 0.000 claims description 10
• 239000013598 vector Substances 0.000 claims description 10
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 9
• 201000011190 diabetic macular edema Diseases 0.000 claims description 9
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
• 208000002780 macular degeneration Diseases 0.000 claims description 8
• 201000010099 disease Diseases 0.000 claims description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
• 239000004094 surface-active agent Substances 0.000 claims description 7
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
• 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
• 101710197658 Capsid protein VP1 Proteins 0.000 claims description 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
• 239000012984 antibiotic solution Substances 0.000 claims description 4
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 3
• 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
• 208000001344 Macular Edema Diseases 0.000 claims description 3
• 206010025415 Macular oedema Diseases 0.000 claims description 3
• 229930195725 Mannitol Natural products 0.000 claims description 3
• 229920002675 Polyoxyl Polymers 0.000 claims description 3
• 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
• 150000001298 alcohols Polymers 0.000 claims description 3
• 239000004359 castor oil Substances 0.000 claims description 3
• 235000019438 castor oil Nutrition 0.000 claims description 3
• SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 3
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
• 230000003902 lesion Effects 0.000 claims description 3
• 201000010230 macular retinal edema Diseases 0.000 claims description 3
• 239000000594 mannitol Substances 0.000 claims description 3
• 235000010355 mannitol Nutrition 0.000 claims description 3
• 229940066429 octoxynol Drugs 0.000 claims description 3
• 229920002113 octoxynol Polymers 0.000 claims description 3
• 229920001983 poloxamer Polymers 0.000 claims description 3
• 229920000136 polysorbate Polymers 0.000 claims description 3
• 229950008882 polysorbate Drugs 0.000 claims description 3
• 239000011780 sodium chloride Substances 0.000 claims description 3
• 239000000600 sorbitol Substances 0.000 claims description 3
• 238000011282 treatment Methods 0.000 claims description 3
• 238000010792 warming Methods 0.000 claims description 3
• 241000288906 Primates Species 0.000 claims description 2
• HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 2
• 229960002028 atropine sulfate Drugs 0.000 claims description 2
• 229960003405 ciprofloxacin Drugs 0.000 claims description 2
• 208000030533 eye disease Diseases 0.000 claims description 2
• 239000002674 ointment Substances 0.000 claims description 2
• 238000009827 uniform distribution Methods 0.000 claims description 2
• 239000003981 vehicle Substances 0.000 claims description 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 239000013646 rAAV2 vector Substances 0.000 claims 2
• -1 Brij Polymers 0.000 claims 1
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
• 238000003756 stirring Methods 0.000 claims 1
• 229920001184 polypeptide Polymers 0.000 description 12
• 102000004196 processed proteins & peptides Human genes 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 241000702423 Adeno-associated virus - 2 Species 0.000 description 7
• 150000001413 amino acids Chemical class 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 108090000565 Capsid Proteins Proteins 0.000 description 3
• 102100023321 Ceruloplasmin Human genes 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 108091008605 VEGF receptors Proteins 0.000 description 3
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
• 239000007971 pharmaceutical suspension Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 239000004141 Sodium laurylsulphate Substances 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1